HOME >> MEDICINE >> NEWS
Patients who need cardiac resynchronization therapy may be eligible for Cedars-Sinai clinical trials

LOS ANGELES (March 8, 2002) Patients who suffer from advanced congestive heart failure and heart rhythm abnormalities may qualify to participate in one of two research trials now underway at Cedars-Sinai Medical Center.

One study is designed to determine whether certain patients who require an implantable defibrillator for life-threatening arrhythmias may enjoy a better quality of life and improved activity level through a combined defibrillator / biventricular pacemaker device.

The other study seeks to enroll patients who are current candidates for biventricular pacemaker therapy (advanced congestive heart failure with delayed impulse conduction) to determine whether cardiac resynchronization therapy alone or in combination with an implantable defibrillator will provide improved patient survival over existing medical therapies.

To be eligible for either study, patients must have advanced congestive heart failure as well as cardiac conduction abnormalities. These conduction abnormalities correlate with worsening congestive heart failure and result in discoordinated contraction of the left and right heart chambers, effectively reducing the forward flow of blood through the heart.

Cardiologists and heart surgeons at Cedars-Sinai Medical Center have offered cardiac resynchronization therapy (CRT) since the introduction of biventricular pacing devices several years ago. These devices, implanted using minimally invasive techniques, stimulate the left and right ventricles to activate in unison, effectively 'resynchronizing' the chambers to contract as they would in a normal heart. Based on already completed clinical trial data showing improvement in heart failure status and activity level, CRT has been approved by the Food and Drug Administration for patients with advanced heart failure and delayed impulse conduction.

Cardiac resynchronization therapy may not, however, prevent irregular heartbeats known as ventricular arrhythmias
'"/>

Contact: Sandra Van
sandy@vancommunications.com
1-800-880-2397
Cedars-Sinai Medical Center
8-Mar-2002


Page: 1 2 3

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patients with cancer have highly increased risk for blood clots
3. Patients with previous heart attacks may not benefit from pacemaker implant
4. Patients with cancer detected on screening mammography undergo less toxic treatment
5. Patients with moderate or severe hand dermatitis responsive to drug therapy
6. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
7. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
8. Patients undergoing weight loss surgery have high rates of H pylori bacteria
9. Patients with chronic sinus do not necessarily develop antibiotic resistance
10. Plastic surgeons honor Patients of Courage overcoming difficult obstacles, inspiring others
11. Patients with severe depression improve using guidelines developed by UT Southwestern researchers

Post Your Comments:
(Date:5/18/2013)... 18, 2013 The “Sleep Apnea Diagnostic ... CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, ... 2017” analyzes and studies the major market drivers, restraints, ... of the World. , Browse , ... 16 Figures , 318 pagesand in-depth ...
(Date:5/18/2013)... 18, 2013 Adolescents, especially young males, ... “Spice” or “K2” are landing in emergency rooms across ... this drug epidemic with a new treatment program ... According to research from the National Institute on Drug ... drug among American teenagers. In 2012, 11 percent of ...
(Date:5/18/2013)... Mexico, DF (PRWEB) May 18, 2013 ... by leading ayurvedic education institution in the West. Program ... Learning education. , Ayurveda is a healing modality practiced ... Ayurvedica ), it is considered that health begins when ... a profound understanding of their individual needs. Ayurveda aims ...
(Date:5/18/2013)... Rio Salon and Spa, a ... renovation that features tranquil, Eastern Asian influenced furnishings, decorative ... up, this Morro Bay day spa and ... and comfortable spa beds. Additional salon stations and new ... machine. The shampoo area has been upgraded and ...
(Date:5/18/2013)... Losing weight remains to be the biggest challenge for ... weight loss products available in the market today, Garcinia Cambogia ... newest weight loss supplement prove that dieting and exercising aren’t ... is a sub-tropical fruit that is shaped like a pumpkin ... a person’s appetite, while it effectively burns fat at the ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The escalation ... proteins, is placing renewed emphasis on alternate delivery ... as a number of factors are converging to ... makers and their delivery device partners . These ... conditions, the growing trend toward self-administration for chronic ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
Cached News: